Stamulumab (MYO-029) is a high-affinity recombinant human antibody and myostatin neutralising antibody capable of increasing muscle mass in SCID mice. It may be employed in studying various muscular dystrophies, such as BMD, FSHD, and LGMD.

Method: Stamulumab (1-10 mg/kg/week, 12 weeks) was administered intraperitoneally to female SCID mice to evaluate its efficacy.
Results: Stamulumab dose-dependently increased skeletal muscle mass, with an Emax value of 23%-30% and a Cave50 range of 47-72 nM. [1]

Human

Monoclonal

Unconjugated